EMG
WST icon

Ellington Management Group’s West Pharmaceutical WST Stock Holding History

Ellington Management Group’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,600
Closed -$539K – 836
2017
Q3 		$539K Buy
+5,600
New +$507K 0.09% 189
2017
Q2 		– Sell
-4,600
Closed -$375K – 929
2017
Q1 		$375K Buy
+4,600
New +$385K 0.01% 399
2014
Q3 		– Sell
-11,000
Closed -$464K – 482
2014
Q2 		$464K Buy
+11,000
New +$471K 0.22% 137

Other funds holding WST

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Ellington Management Group's WST Position: Q4 2017 in Review

Ellington Management Group sold out of West Pharmaceutical (WST) in Q4 2017, closing a stake of 5,600 shares — an estimated $539K sold.

Ellington Management Group first reported a position in WST in Q2 2014 and held it in 3 quarters. The position peaked at $539K in Q3 2017. 338 funds tracked by Wall St. Rank hold WST as of Q4 2017.

  • Ellington Management Group reported no remaining West Pharmaceutical position as of Q4 2017 after selling out during the quarter.
  • Ellington Management Group sold 5,600 West Pharmaceutical shares in Q4 2017, an estimated $539K.
  • Ellington Management Group first reported a position in West Pharmaceutical in Q2 2014 and held it in 3 quarters.
  • Ellington Management Group's West Pharmaceutical position peaked at $539K in Q3 2017.
  • 338 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2017.

Based on Ellington Management Group's 13F filing for Q4 2017, filed 14 Feb 2018.